News
9h
Medpage Today on MSNJAK Inhibitors' Cancer Risk Confirmed in Real-World DataThe RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...
Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...
StockStory.org on MSN1d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
15h
Zacks.com on MSNAmgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...
Eagles star Dallas Goedert opens up about a lifelong struggle that he has become a proud spokesperson for with his latest ...
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results